Jump to content
RemedySpot.com

Re: Dr. Furman on TRU-016 ~ASH

Rate this topic


Guest guest

Recommended Posts

Happy New Year Everyone!

It's been awhile since I posted as we have been busy enjoying the arrival of our

first grandchild. I thought I would give a brief update on how my husband has

been doing.

My husband was diagnosed in 2003 with atypical CLL. He was asymptomatic and on

W & W until May of 2009 when he was suddenly diagnosed with a Richter's

transformation in his spleen. (DLBCL) He was treated quickly with R-CHOP (two

week cycle) at Sloan-Kettering. He responded immediately with only minor

side-effects and continues to enjoy remission of both the DLBCL as well as his

CLL. His blood work is completely within normal range and his immune system has

been functioning well.

We have been following the discussions regarding therapeutic agents that will

hopefully transform CLL into a chronic manageable disease. We realize these

agents are still in clinical trial stages. Realistically, assuming the data

collected continues to be favorable, how long might it be until CLL can be

treated as a chronic disease?

Stella- dx 2003 atypical CLL t(11;14) cyclin D-1 neg. asymptomatic, W & W

until May 2009, Richter's Transformation in spleen (DLBCL)treated with R-CHOP

(14 day cycle)CR- normal blood work 

From: cllcanada <cllcanada@...>

Subject: Dr. Furman on TRU-016 ~ASH

Date: Monday, December 6, 2010, 10:40 PM

 

" Novel agents that are more effective and better tolerated are needed to help

transform CLL into a truly chronic condition. Of the therapeutics currently in

development, targeting CD37 with TRU-016 appears to be among the most promising.

"

Emergent is pursuing development of TRU-016, a novel CD37-targeted therapy for

the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL)

developed under our Abbott collaboration. TRU-016 uses a different mechanism of

action than CD20-directed therapies and has demonstrated potent antitumor

activity in its preclinical evaluation and now in Phase 1 clinical study.

Source: Businesswire:http://tinyurl.com/2g9hyyt

More ~ Emergent Biosolutions: http://www.truemergent.com/tru-016/

~chris

CLL CANADA

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...